Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
30 participants
INTERVENTIONAL
2017-06-15
2019-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Detection of Circulating Tumor Cells (CTCs) in Patients With Lung Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
NCT02412384
Interventional Ablation for Early-stage Lung Cancer
NCT07005999
A Clinical Study of the Cryoablation Technique for Peripheral Lung Malignancies
NCT06832969
Bioinformation Therapy for Lung Cancer
NCT03239171
A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients
NCT03429673
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
NOTE: Originally, our designed proposal was to use autologous PBMCs from cancer patients to ex vivo expand Vγ9Vδ2-T cells, and then perform adoptive transfer therapy. However, PBMCs of majority of cancer patients could not be effectively expanded, including cell number, cell purity and cell function could not meet the requirements of reinfusion. Meanwhile, those patients could not tolerate 100ml of blood drawing for culture every 2 \~ 3 weeks.
Therefore, we submitted new clinical study application to the ethical committee of the Fuda Hospital affiliated with Jinan University (Guangzhou, PR. China) by changing the autologous protocol with the allogeneic protocol. After the allogeneic protocol was approved, we adapted allogeneic cells instead of autologous in our subsequentially clinical study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor
Cryosurgery or IRE surgery
Cryosurgery or IRE surgery will be used in local tumor
Group B
In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
γδ T cell
γδ T cells will be used against Lung Cancer
Group C
In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
γδ T cells/ A Cryosurgery or IRE
Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cryosurgery or IRE surgery
Cryosurgery or IRE surgery will be used in local tumor
γδ T cell
γδ T cells will be used against Lung Cancer
γδ T cells/ A Cryosurgery or IRE
Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jinan University Guangzhou
OTHER
Fuda Cancer Hospital, Guangzhou
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jibing Chen, PhD
Role: PRINCIPAL_INVESTIGATOR
Biological treatment center in Fuda cancer hospital Guangzhou, Guangdong, China, 510000
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Biotherapy center in Fuda cancer hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Gd T cell and lung Ca
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.